RT Journal Article
SR Electronic
T1 Body Fatness Increases Risk of Monoclonal Gammopathy of Undetermined Significance in the U.S. Population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.10.24314907
DO 10.1101/2024.10.10.24314907
A1 Ji, Mengmeng
A1 Huber, John
A1 Wang, Mei
A1 Shih, Yi-Hsuan
A1 Lan, Tuo
A1 Wang, Shi-Yi
A1 Chang, Su-Hsin
YR 2024
UL http://medrxiv.org/content/early/2024/10/11/2024.10.10.24314907.abstract
AB Objective Current evidence on whether obesity is associated with MGUS remains inconsistent. This study aims to evaluate the association between objectively measured obesity markers and the risk of developing MGUS, using nationally representative data from the U.S. population.Method Data came from the third National Health and Nutrition Examination Survey III (1988-1994) and continuous NHANES (1999-2004). Multivariable-adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for the association between the risk of developing MGUS and seven obesity markers—including baseline body mass index (BMI), maximum lifetime BMI, waist circumference (WC), waist-hip ratio (WHR), total body fat, fat-free mass, and body percentage fat—were estimated using logistic regression.Results In the study cohort, a total of 364 participants tested positive for MGUS, compared to 12,043 participants without MGUS. Multivariate logistic regression analysis indicates that each 1% increase in body fat percentage is associated with a 4% (aOR: 1.04, 95% CI [1.01, 1.07]) higher risk of MGUS. Each 1% increase in body fat percentage is also associated with a 6% (aOR: 1.06, 95% CI [1.02, 1.10]) higher risk of non-IgM MGUS. No statistically significant association was found between MGUS and other obesity markers, including baseline BMI, maximum lifetime BMI, WC, WHR, and fat-free mass.Conclusion Our findings show that obesity is associated with an increase in the risk of MGUS. However, many obesity markers, including the commonly used BMI, fail to capture this association.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Cancer Institute of the National Institutes of Health under Award Numbers U01CA265735.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at:https://www.cdc.gov/nchs/nhanes/index.htmI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript